. Author manuscript; available in PMC: 2013 Dec 1.

Published in final edited form as: Mol Cancer Ther. 2013 Mar 19;12(6):959–967. doi: 10.1158/1535-7163.MCT-12-0707

Table 2. Cytotoxicity of etoposide, doxorubicin and camptothecin, alone and in combination with KU59403 in LoVo and SW620 cells.

Cytotoxic drug	SW620			LoVo
	% Survival		Enhancement factor^†	% Survival		Enhancement factor
	Cytotoxic alone	Cytotoxic + KU59403	Enhancement factor^†	Cytotoxic alone	Cytotoxic + KU59403	Enhancement factor
Etoposide 100 nM	89 ± 8.3	35 ± 12^**	2.9 ± 1.5	58 ± 8.3	18 ± 0.5^**	3.3 ± 0.4
Etoposide 1 μM	3.8 ± 1.1	0.41 ± 0.23^*	12 ± 7	3.9 ± 0.8	1.1 ± 0.2^*	3.8 ± 1.5
Doxorubicin 10 nM	50 ± 9	17 ± 0.2^*	2.9 ± 0.6	47 ± 3.1	16 ± 6.9^*	3.2 ± 1
Doxorubicin 100 nM	0.02 ± 0.01	0.01 ± .001	1.8 ± 0.7	2.1 ± 0.5	0.35 ± 0.04^*	6.1 ± 2.1
Camptothecin 10 nM	2.4 ± 0.2	0.71 ± 0.35^*	4.3 ± 2.8	33 ± 7.9	6.2 ± 3. 8^*	6.9 ± 3.8

Cells were exposed to etoposide or doxorubicin, at the concentrations indicated, alone or in combination with 1 μM KU59403 in a final concentration of 0.5% (v/v) DMSO for 16 hr. Data, normalised in comparison with DMSO or KU59403 alone control, as appropriate, are the mean ± standard deviation of 3 independent experiments. Significant differences between cytotoxic drug alone versus cytotoxic + KU59404 is given by

p=<0.05

and

^**

p<0.01

^†

Enhancement factor is defined as the survival with the cytotoxic alone ÷ survival with cytotoxic + KU59403 in each individual experiment, and data are the mean ± standard deviation of 3 independent experiments.